FMP
Marker Therapeutics, Inc.
MRKR
NASDAQ
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
1 USD
-0.1 (-10%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
9.33M
54.73M
39.04M
46.41M
43.15M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-
-
-
-
-
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-
-
-
-
-
-
-
-
-
-
100
100
100
100
100
100
100
100
100
1.39M
560k
648k
427k
1.01M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-180.29k
-367.89k
-115k
-33k
-37k
-
-
-
-
-
100
100
100
100
100
-
-
-
-